Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling

被引:27
|
作者
Reid, Samantha
Johnson, Lacey
Woodland, Narelle
Marks, Denese C. [1 ]
机构
[1] Australian Red Cross Blood Serv, Appl & Dev Res, Res & Dev, Alexandria, NSW 2015, Australia
关键词
STORAGE LESION DEVELOPMENT; CELL-DEATH; PHOSPHATIDYLSERINE EXPOSURE; CASPASE ACTIVATION; APOPTOSIS; BAX; PLASMA; RIBOFLAVIN; MIRASOL; INACTIVATION;
D O I
10.1111/j.1537-2995.2011.03558.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Pathogen reduction technology (PRT) can potentially reduce the risk of transfusion-transmitted infections. However, PRT treatment of platelet (PLT) concentrates also results in reduced PLT quality and increased markers of apoptosis during storage. The aim of this study was to investigate changes to the expression and activation of proteins involved in apoptosis signaling. STUDY DESIGN AND METHODS: Samples from riboflavin and ultraviolet light PRT-treated and untreated (control) buffy coat-derived PCs in 70% SSP+ and 30% plasma were taken on Days 1, 5, and 7 of storage. Phosphatidylserine (PS) exposure, expression of Bcl-2 family proteins, cytochrome c release, and cleavage of caspase-3 and caspase-3 substrates were analyzed using flow cytometry and Western blotting. RESULTS: Compared to untreated controls, markers of apoptosis signaling were increased after PRT and subsequent storage. PS exposure on the PLT outer membrane was significantly higher after PRT on Days 5 and 7 of storage (p < 0.05). Expression of proapoptotic Bak and Bax was higher after PRT and subsequent storage. Cytochrome c release and caspase-3 cleavage were also greater and occurred earlier in the PRT-treated PLTs. The cleavage of caspase-3 substrates gelsolin and ROCK I were also increased after PRT, compared to untreated controls. CONCLUSIONS: This study demonstrated an increase in proapoptotic signaling during PLT storage, which was exacerbated by PRT. Many of these differences emerged outside the current 5-day storage period. These changes may not currently influence PLT transfusion quality, but will need to be carefully evaluated when considering extending PLT storage beyond 5 days.
引用
收藏
页码:2094 / 2103
页数:10
相关论文
共 50 条
  • [1] Treatment of Buffy Coat Platelets in Platelet Additive Solution with the Mirasol® Pathogen Reduction Technology System
    Castrillo, Azucena
    Cardoso, Marcia
    Rouse, Lindsay
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2013, 40 (01) : 44 - 48
  • [2] Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution
    Slichter, Sherrill J.
    Bolgiano, Doug
    Corson, Jill
    Jones, Mary Kay
    Christoffel, Todd
    Bailey, S. Lawrence
    Pellham, Esther
    [J]. TRANSFUSION, 2014, 54 (09) : 2283 - 2291
  • [3] Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat- derived platelet concentrates
    Loh, Yen S.
    Johnson, Lacey
    Kwok, Matthew
    Marks, Denese C.
    [J]. TRANSFUSION, 2014, 54 (03) : 577 - 584
  • [4] Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution
    Johnson, L. N.
    Winter, K. M.
    Reid, S.
    Hartkopf-Theis, T.
    Marks, D. C.
    [J]. CRYOBIOLOGY, 2011, 62 (02) : 100 - 106
  • [5] MIRASOL® PATHOGEN REDUCTION TECHNOLOGY TREATMENT OF ORBISAC BUFFY COAT PLATELETS SUSPENDED IN ADDITIVE SOLUTION
    Maia, S.
    Rio, N.
    Marques, S.
    Rouse, L.
    [J]. VOX SANGUINIS, 2010, 99 : 245 - 246
  • [6] IN VITRO QUALITY TEST OF PLATELET CONCENTRATES FROM BUFFY COAT AND APHERESIS IN ADDITIVE SOLUTION, TREATED WITH TWO PATHOGEN INACTIVATION SYSTEMS
    Castrillo, A.
    Arcas, C.
    Castro, A.
    Eiras, A.
    Adelantado, M.
    Areal, C.
    Rodriguez, M., I
    [J]. VOX SANGUINIS, 2010, 99 : 249 - 250
  • [7] TREATMENT OF ORBISAC DERIVED BUFFY COAT PLATELETS WITH THE MIRASOL® PATHOGEN REDUCTION TECHNOLOGY AND STORAGE IN ADDITIVE SOLUTION
    Reikvam, H.
    Hervig, T.
    Marschner, S.
    Goodrich, R.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 284 - 284
  • [8] Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology
    Ostrowski, Sisse R.
    Bochsen, Louise
    Windelov, Nis A.
    Salado-Jimena, Jose A.
    Reynaerts, Inge
    Goodrich, Raymond P.
    Johansson, Par I.
    [J]. TRANSFUSION, 2011, 51 (02) : 344 - 356
  • [9] Quality assessment and transfusion efficacy of buffy coat-derived platelet concentrates washed with platelet additive solution
    Fernandez-Munoz, Hermogenes
    Castilla-Llorente, Cristina
    Plaza, Eva M.
    Martinez-Millan, Cristina
    Heras, Inmaculada
    Iniesta, Pastora
    Amigo, Maria L.
    Ferrer-Marin, Francisca
    Candela, Maria J.
    Lozano, Maria L.
    Vicente, Vicente
    Rivera, Jose
    [J]. BLOOD TRANSFUSION, 2018, 16 (03) : 273 - 278
  • [10] In Vitro Evaluation of Platelet Concentrates from Buffy Coat Treated with Two Pathogen Reduction Technology (PRT)
    Castrillo Fernandez, A.
    Arcas Otero, C.
    Diaz Pereira, A.
    Rodriguez Calvo, M.
    [J]. TRANSFUSION, 2011, 51 : 54A - 54A